Abelardo Aguilera Peralta

Autonomous University of Madrid Spain

Dr. Abelardo Aguilera Peralta was born in Tegucigalpa, Honduras on June 3, 1967. He obtained the title of general practitioner in 1989 at the Facultad de Medicina de la Universidad Nacional Autónoma de Honduras, en Tegucigalpa. He studied Nephrology at the Hospital Ramón y Cajal, from Madrid, Spain (1991-1994) and obtained the title of Doctor (Ph.D) in the Universidad Autónoma de Madrid (2007). He was also a Pre-doctoral fellow at the Nephrology Institute, Cardiff, Wales, UK (1999-2000). Currently Dr. Aguilera is a senior researcher from Miguel Servet Program at the Hospital Universitario de la Princesa, Madrid, since 2007. Dr. Aguilera has also more than 100 scientific articles published mainly in international journals, among which the New Engl J Med, J Am Soc Nephrol, Lab Investigation, Plos One, etc. He has received more than 25 national and international awards, has a degree in Physics as well as a specialist in family medicine and is Reviewer and editor of several international journals. Finally his main research areas are epithelial-to-mesenchymal transition of mesothelial cells and peritoneal membrane failure, and disorders in appetite regulation on dialysis patients.

Abelardo Aguilera Peralta

1books edited

3chapters authored

Latest work with IntechOpen by Abelardo Aguilera Peralta

This book summarizes the advances and new concepts introduced in the last years on peritoneal dialysis (PD) and its complications. PD therapy is a renal replacement peritoneal membrane using a semi-permeable barrier to liquids and solutes. The abdominal cavity with all its components, mesothelial cells, fat tissue, immune system components and others are activated by the PD fluids that although every time are more biocompatible, induce production of molecules with the local and systemic effects. Locally there is a thickening of the peritoneal membrane leading to the failure of this and where the transdifferentiation of mesothelial cells plays a key role. Systemically activating abdominal cavity appears to be involved in atherosclerosis, diabetes, hypertension, renal bone disease pathway and others.

Go to the book